CytoDyn Presents Promising Data on Leronlimab for Metastatic Breast Cancer

Novel CCR5 inhibition mechanisms and long-term survival signals highlighted at AACR Immuno-Oncology Conference

Published on Mar. 1, 2026

Got story updates? Submit your updates here. ›

CytoDyn Inc. announced the presentation of new preclinical, translational, and clinical data supporting leronlimab's potential role in treating metastatic triple-negative breast cancer at the AACR Immuno-Oncology Conference. The data explores how leronlimab, a CCR5 receptor antagonist, may enhance responses to immune checkpoint inhibitors by modulating the tumor immune microenvironment.

Why it matters

Triple-negative breast cancer is an aggressive form of the disease with limited treatment options, so new therapies that can improve outcomes are highly sought after. Leronlimab's novel mechanism of action targeting the CCR5 receptor could provide a new approach to enhancing immunotherapy responses in these patients.

The details

In preclinical studies, leronlimab was shown to induce PD1 expression in T cells and reduce the secretion of immunosuppressive mediators from triple-negative breast cancer cells. In a retrospective analysis of 28 heavily pretreated metastatic triple-negative breast cancer patients, leronlimab demonstrated a favorable safety profile and 17.9% of patients remained alive after more than 63 months of follow-up.

  • The AACR Immuno-Oncology Conference was held from February 18-21, 2026 in Los Angeles, California.
  • The retrospective clinical analysis included data from three clinical trials with a median follow-up of more than 63 months.

The players

CytoDyn Inc.

A biotechnology company developing leronlimab, a CCR5 receptor antagonist, for the treatment of various diseases including cancer.

Leronlimab

An investigational CCR5 receptor antagonist being evaluated for its ability to modulate the tumor immune microenvironment and enhance responses to immune checkpoint inhibitors.

Got photos? Submit your photos here. ›

The takeaway

The promising data on leronlimab's ability to modulate the tumor immune microenvironment and potentially enhance immunotherapy responses in metastatic triple-negative breast cancer patients highlights the potential of this novel CCR5-targeting approach to address an unmet need in this aggressive form of the disease.